Last reviewed · How we verify
Anitocabtagene autleucel
Anitocabtagene autleucel is a chimeric antigen receptor (CAR) T-cell therapy that targets the B-cell maturation antigen (BCMA) on multiple myeloma cells.
Anitocabtagene autleucel is a chimeric antigen receptor (CAR) T-cell therapy that targets the B-cell maturation antigen (BCMA) on multiple myeloma cells. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | Anitocabtagene autleucel |
|---|---|
| Also known as | CART-ddBCMA |
| Sponsor | Kite, A Gilead Company |
| Drug class | CAR T-cell therapy |
| Target | BCMA |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This CAR T-cell therapy works by removing T-cells from a patient's blood, genetically modifying them to recognize and bind to BCMA on myeloma cells, and then reinfusing the modified T-cells to attack and kill the cancer cells. The BCMA-targeting CAR T-cells can induce a sustained anti-myeloma response and potentially lead to long-term remission.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
- Thrombocytopenia
- Infections
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anitocabtagene autleucel CI brief — competitive landscape report
- Anitocabtagene autleucel updates RSS · CI watch RSS
- Kite, A Gilead Company portfolio CI